Rtw Investments Adds $4M in Evommune, Inc. ($EVMN)
Rtw Investments increased its EVMN holdings by 218,564 shares, a 17% rise.
Key Points
- Rtw Investments grew its EVMN position by 17%, adding 218,564 shares to reach a total of 1,502,235 shares.
- EVMN shares recently traded at $19.83 with a market value of approximately $29.79 million for Rtw's holdings.
- Analysts like HC Wainwright & Co. and Morgan Stanley maintain a 'buy' rating on EVMN with price targets of $50 and $55 respectively.
Rtw Investments has increased its stake in EVMN, adding 218,564 shares according to its latest Form 13F filing with the SEC. This move, recorded as of the reporting period ending March 31, 2026, boosts Rtw's holdings by 17% to a total of 1,502,235 shares. The value of this position now stands at approximately $29.79 million.
What Changed in Rtw Investments' EVMN Position
Rtw Investments' decision to add 218,564 shares represents a 17% increase from its previous holding of 1,283,671 shares. This brings its total to 1,502,235 shares, valued at about $29.79 million. This adjustment reflects a strategic decision to strengthen its position in EVMN.
Other Institutional Activity in EVMN
Several other funds have also shown interest in EVMN. EQT Fund Management S.A R.L. kept its holdings steady at 4,929,633 shares, valued at approximately $113.33 million. RA Capital Management, L.P. increased its stake by 35,868 shares, reaching a total of 3,494,638 shares worth about $80.34 million. Meanwhile, Pivotal BioVenture Partners Investment Advisor LLC and Andera Partners maintained their positions with 1,926,943 and 1,897,362 shares, valued at $44.30 million and $43.62 million, respectively. JPMorgan Chase & Co. also increased its holdings by 150,519 shares, bringing its total to 1,459,420 shares, valued at approximately $32.11 million.
EVMN Stock Snapshot
Shares of EVMN recently traded at $19.83. While specific financial ratios and market capitalization data are not available, the stock's trading price provides a snapshot of its current market perception.
Analysts Set New Price Targets
Analysts have shown confidence in EVMN, with several firms maintaining a 'buy' rating. On May 26, 2026, HC Wainwright & Co. reiterated its 'buy' rating with a price target of $50. Morgan Stanley maintained its 'buy' rating with a price target of $55 on May 11, 2026. RBC Capital also reaffirmed a 'buy' rating with a $48 target back in April. The consensus among analysts is a strong buy, with a mean target price reflecting optimism about the company's potential.
About EVMN
EVMN operates in a sector that was not specified, focusing on innovative solutions and services. The company is committed to advancing its industry through research and development, aiming to deliver value to its stakeholders. EVMN is based in an unspecified location and continues to grow its market presence.
Bottom Line
Rtw Investments' decision to increase its stake in EVMN by 17% highlights its confidence in the company's potential. While 13F filings are historical and may not represent current positions, they provide insight into institutional sentiment. Analysts' positive ratings further bolster the outlook for EVMN, making it a stock to watch in the coming months.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.